No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 4 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Alps Group Inc (ALPS) stock was $0.40 as of Oct 5, 2026, 4:00 PM EDT, up 1.27% from the previous close.
Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge therapeutic solutions.
Biotechnology · Kuala Lumpur, WP
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.24
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALPS | $66.56M | $0.40 | +1.27% | N/A | N/A | N/A | N/A |
| 2PDSB | $67.11M | $1.20 | +60.32% | +17.56% | -39.13% | -40.75% | vs ALPS |
| 3GOSS | $65.08M | $10.65 | -0.56% | -94.75% | -59.51% | N/A | vs ALPS |
| 4INCR | $64.56M | $5.45 | +0.55% | -32.59% | -30.85% | N/A | vs ALPS |
| 5CSBR | $69.05M | $4.97 | +0.61% | -21.02% | -13.07% | +12.07% | vs ALPS |
| 6CING | $63.98M | $4.75 | -0.21% | +13.57% | N/A | N/A | vs ALPS |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.40
High
N/A
